Zepbound maker and drug giant Eli Lilly's (LLY) stock is in the buy zone of a flat base after hitting a new high. The IBD Sector Leaders name is in a race with Novo Nordisk (NVO) in the fast-growing weight-loss medication industry. Lilly makes injectable obesity drug Zepbound and Type 2 diabetes treatment Mounjaro.
It launched its weight-loss pill Foundayo in…
Extract — continue reading at the source.
Similar stories
1 outlet
Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars
finance.yahoo.com
24.08.2026
Related stories
The ugly math on interest expenses, yields and the $40 trillion U.S. national debt
Stanley Druckenmiller takes aim at former colleague Scott Bessent
Dimension Energy Secures $857 Million to Support Distributed Solar
Why nCino Stock Is Rising Today
CrowdStrike earnings: Investors demand acceleration signal, not just a beat
Stock Market Midday, Aug. 26: Markets Muted as Investors Await Nvidia Earnings